Juergen E. Gschwend - Concepedia

Author

Juergen E. Gschwend

Also Known As

C.-H. Ohlmann, J E Gschwend, J Gschwend, J. E. Gschwend, J. Gschwend, J.E. Gschwend, JUERGEN E. GSCHWEND, Juergen E Gschwend, Juergen E. Gschwend, Juergen Erich Gschwend

180

Publications

4.9K

Citations

H-Index

Concepts

All Affiliations

Technical University of Munich Universität Ulm Klinikum rechts der Isar University Hospital Ulm University of Michigan

About

Juergen E. Gschwend is an author at Technical University of Munich specializing in oncology, medicine, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	28	2K
2	Health Sciences	5	5	678
3	Cell Biology	5	5	339
4	Engineering	2	2	591
5	Public Health	1	1	13

Juergen E. Gschwend

Publications

Citations

H-Index

Page 1

	Year	Citations
Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer Matthias Eiber, Gregor Weirich, Konstantin Holzapfel, European Urology EngineeringOncologic ImagingMedical ImagingPet-mriBiomedical Imaging	2016	567
Prostate-specific membrane antigen expression as a predictor of prostate cancer progression Sven Perner, Matthias D. Hofer, Robert Kim, Human Pathology UrologyPerineural InvasionGenitourinary CancerPathologyProstate Cancer Progression	2007	457
Survival Benefit of Radical Prostatectomy in Lymph Node–Positive Patients with Prostate Cancer Jutta Engel, Patrick J. Bastian, H. Baur, European Urology UrologySurgical OncologyMedicineRadical ProstatectomyLymph Node–positive Patients	2010	262
Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer Rainer Kuefer, Matthias D. Hofer, Vedat Altug, British Journal of Cancer	2004	152
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial Daniel P. Petrylak, Nicholas J. Vogelzang, Nikolay Budnik, The Lancet Oncology UrologyPlacebo-controlled Phase 3Genitourinary CancerMedicineClinical Trials	2015	147
α-Methylacyl-CoA Racemase: Expression Levels of this Novel Cancer Biomarker Depend on Tumor Differentiation Rainer Kuefer, Sooryanarayana Varambally, Ming Zhou, American Journal Of Pathology Tumor BiologyExpression LevelsOncologyTumor DifferentiationEpigenetic Regulation	2002	139
Disease Specific Survival as Endpoint of Outcome for Bladder Cancer Patients Following Radical Cystectomy Juergen E. Gschwend European Urology Radical CystectomyUrologySurgical OncologyUrological ResearchGenitourinary Cancer	2002	136
Evaluation of [ <sup>11</sup> C]‐choline positron‐emission/computed tomography in patients with increasing prostate‐specific antigen levels after primary treatment for prostate cancer L. Rinnab, Felix M. Mottaghy, Norbert M. Blumstein, British Journal of Urology	2007	132
The Role of Metastasis-Associated Protein 1 in Prostate Cancer Progression Matthias D. Hofer, Rainer Kuefer, Sooryanarayana Varambally, Cancer Research	2004	129
The Sensitivity of [11C]Choline PET/CT to Localize Prostate Cancer Depends on the Tumor Configuration Michael Souvatzoglou, Gregor Weirich, Sarah Schwarzenboeck, Clinical Cancer Research	2011	103

Page 1